

August 14, 2020

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sirs,

Sub: Outcome of the Board Meeting – 14th August, 2020

The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on August 14, 2020, considered and approved the following:

- A. Appointment of Mr. Dipankar Bhattacharjee (DIN: 08770548) as an Additional Director to hold office as an Independent Director of the Company for a period of five years with effect from 14th August, 2020, not liable to retire by rotation, subject to the approval of the members of the Company in the ensuing Annual General Meeting. Mr. Dipankar Bhattacharjee is not debarred from holding the office of director by virtue of any order passed by SEBI or any other authority.

Accordingly, please find enclosed the requisite information as required under SEBI Circular dated 9th September, 2015 in Annexure A, content of which is self-explanatory.

B. Recommendation of Appointment of Statutory Auditors:

With reference to the captioned subject, we wish to inform you that the Board of Directors, based on the recommendation of the Audit Committee, have, at their meeting held on 14th August, 2020, recommended the appointment (for the approval of the shareholders) of M/s Suresh Surana & Associates, Chartered Accountants (Firm Registration No.121750W/W-100010) as Statutory Auditors of the Company, as the term of existing auditors M/s Walker Chandio & Co LLP will end at the conclusion of the ensuing AGM, in accordance with provisions of Section 139 of the Companies Act, 2013 read with rules made thereunder.

The appointment of Statutory Auditors will be placed before the Members for their approval at the ensuing 42nd Annual General Meeting of the Company.

The details of the Statutory Auditors as required under SEBI circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 is enclosed herewith as Annexure B.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.



Harish Kuber
Company Secretary & Compliance Officer

Encl: As above

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

Annexure A

Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015

Sr. No.	Particulars	Details
1.	Name of Director	Mr. Dipankar Bhattacharjee (DIN: 08770548)
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment
3.	Date of appointment & term of appointment	Appointment of Mr. Dipankar Bhattacharjee (DIN: 08770548) as an Additional Director - Independent Director of the Company for a period of five years w.e.f. 14th August, 2020, not liable to retire by rotation, subject to approval of the members of the Company.
4.	Brief Profile (in case of appointment)	Mr. Dipankar Bhattacharjee has over 30 years of global experience in leading Generics, Specialty and OTC Pharma, Medical Devices, and FMCG businesses. Mr. Dipankar have led high performing teams to develop and execute business strategies across all stages of business cycles, driving growth and value through commercial innovation and focused R&D investments. Mr. Dipankar was associated with Teva group from 2009 to 2017. In his recent stint with Teva, he was President & CEO - Global Generics Medicines, Officer and Member of Teva Executive Committee (TEC). He played major role during his tenure with Teva as President & CEO of Teva Europe Generics; Senior Vice President of Teva Western Europe; Chief Executive Officer of Teva UK Ltd.

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com



		Prior to Teva he had worked with Bausch & Lomb & Bank of America. Mr. Dipankar has Bachelors degree in Economics from University of Delhi, India and has also done Master of Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Bombay, India.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Dipankar Bhattacharjee is not related to any Board Member of the Company.



Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Information as required under SEBI circular No. CIR/CFD/CMD/4/2015 dated 9 September 2015

Sr. No.	Particulars	Details
1.	Reason for change viz., appointment, resignation, removal, death or otherwise	Pursuant to the provisions of Section 139 of the Companies Act, 2013 read with rules made thereunder, an audit firm can be appointed as statutory auditors for a maximum of two terms of 5 consecutive years. M/s. Walker Chandiok & Co LLP, the Statutory Auditors hold office until the conclusion of the 42nd Annual General Meeting (AGM) of the Company and are not eligible for reappointment for another term as per Section 139 of the Companies Act, 2013. In this regard, the Board recommended the appointment of M/s Suresh Surana & Associates, Chartered Accountants (Firm Registration No.121750W/W-100010) as the Statutory Auditors for approval of the Members at the ensuing 42nd AGM of the Company.
2.	Date of appointment / -cessation (as applicable) & term of appointment;	The appointment of M/s. Suresh Surana & Associates, Chartered Accountants (Firm Registration No. 121750W/W-100010) as Statutory Auditors of the Company shall be for a term of 5 consecutive years from the conclusion of the 42th AGM till the conclusion of 47th AGM of the Company.
3.	Brief profile (in case of appointment);	•Suresh Surana & Associates LLP ("SSA") is the Indian member firm of RSM Network and RSM US is the 5th largest accounting and consulting firm in the United States. •SSA/RSM Astute Consulting Group along with its affiliates (together referred as 'RSM

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com



		India') consistently ranks amongst India's top 6 audit, tax and consulting groups [International Accounting Bulletin-India Surveys 2011-18]. •Group strength of about 1,800 personnel •PAN – India presence with offices in 11 key cities •Core services include Assurance Services, Internal Audits & Risk Advisory, Corporate Tax & GST, IT Systems Assurance & Solutions and Operations Consulting •Multi-disciplinary personnel comprising of CAs, MBAs, Engineers, CMAs, CISAs/ISAs, Forensic Professionals, Company Secretaries & Law Graduates, etc. •Clients include several large Indian groups, multinational corporations and first-generation entrepreneur.
--	--	--



Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com